Literature DB >> 18771926

Primary intracranial low-grade fibromyxoid sarcoma (Evans tumor).

Kagan Tun1, Ozlem Ozen, Erkan Kaptanoglu, Oktay Gurcan, Ethem Beskonakli, Bulent Celasun.   

Abstract

Low-grade fibromyxoid sarcoma was first described in 1987 as a rare soft tissue neoplasm characterized by a bland and deceptively benign histological appearance but with aggressive behavior. A 20-year-old male patient presented with a recent history of headache and seizure. A right frontal mass was detected on MRI and he was operated upon to remove the intracranial mass. Histological examination revealed mildly atypical fibroblastic cells embedded within a myxoid matrix. Nuclear atypia and pleomorphism were minimal, and necrosis was not present. The lesion was diagnosed as a low-grade fibromyxoid sarcoma. Although primary intracranial low-grade fibromyxoid sarcoma has characteristic histological features, clinical and radiological correlation is necessary to make the correct diagnosis.

Entities:  

Mesh:

Year:  2008        PMID: 18771926     DOI: 10.1016/j.jocn.2007.07.085

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

1.  Primary paravertebral low-grade fibromyxoid sarcoma.

Authors:  Woo Jin Lee; Chong Oon Park; Seung Hwan Yoon; Young Chae Chu
Journal:  J Korean Neurosurg Soc       Date:  2010-11-30

2.  The clinical significance of the FUS-CREB3L2 translocation in low-grade fibromyxoid sarcoma.

Authors:  Barry Rose; George S Tamvakopoulos; Kamaljit Dulay; Robin Pollock; John Skinner; Timothy Briggs; Steven Cannon
Journal:  J Orthop Surg Res       Date:  2011-03-15       Impact factor: 2.359

3.  Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis.

Authors:  Francis Shih; Stephen Yip; Patrick J McDonald; Albert E Chudley; Marc R Del Bigio
Journal:  Acta Neuropathol Commun       Date:  2014-10-21       Impact factor: 7.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.